Learn More NuPathe IR Fact Sheet
12% of adult Americans suffer from debilitating migraine symptoms, including headache pain and migraine-related nausea. Learn more
Learn more about how NuPathe views the biopharmaceutical business, the issues facing today’s patients, and why we are driven to do what we do. Read Now
Chief Executive Officer Chief Financial Officer
NuPathe is a biopharmaceutical company with a late-stage asset that addresses needs in a large patient population. In three Phase 3 clinical trials involving more than 10,000 patch applications, the migraine patch offered patients fast onset and sustained relief of both migraine headache pain and migraine-related nausea. All worldwide rights to the migraine patch are owned exclusively by NuPathe, providing long-term commercial value. IP protection in the U.S. through 2027 NuPathe owns 100% of the economics. NuPathe’s transformative SmartRelief technology positions the company to capitalize on the rapidly expanding global transdermal market (forecasted to increase from $21.5 to $31.5 billion by 2015), by potentially opening entirely new classes of medications for delivery through the skin. NuPathe’s earlier stage pipeline addresses significant worldwide opportunities in Parkinson’s disease, schizophrenia, and bipolar disorder.